SaverOne: The Defense Option Opened, But Dilution Still Runs The Story

Introduction To The Company

SaverOne is still not a proven software company, and it is not yet a proven defense company either. At the end of 2025 it remains a very small commercialization story whose only product with partial market proof is its DDPS solution for preventing driver distraction in vehicle fleets. The OEM line is still in development, the ADAS line is still in development, and after the balance sheet date a new layer was added, an RF defense platform tied to VisionWave. That is why the easiest reading mistake here is to confuse the breadth of the story with the depth of the revenue base.

What is working now is real enough. The company has an installed product, legitimate reference accounts, and commercial activity that is no longer Israel-only. European revenue rose to NIS 566 thousand in 2025 from NIS 489 thousand in 2024, while Israel fell to NIS 450 thousand. The company also has names that matter for market credibility, including Teva in Israel and a growing Cemex footprint across Europe. Operating loss narrowed to NIS 30.7 million from NIS 33.3 million a year earlier, largely because selling and G&A costs came down.

But the picture is still not clean. Full-year revenue was only NIS 1.016 million, gross profit flipped to a gross loss of NIS 74 thousand after a NIS 377 thousand inventory write-down, and the company ended the year with NIS 14.1 million of cash only because financing cash inflow reached NIS 32.1 million. At the same time, the audited equity note shows the share count jumping from 415.1 million to 10.26 billion in a single year. The active bottleneck is therefore no longer just commercialization. It is whether the company can fund the bridge period without destroying per-share economics on the way.

This matters now because after year-end the company sold another 17.5 billion shares to Yorkville for $2.485 million, and also completed Stage 1 of the VisionWave deal, under which it committed to issue another 6.42 billion shares. So 2026 does not read like a normal commercialization year. It reads like a reset-and-proof year: SaverOne has to show both broader proof of demand for the legacy product and evidence that the defense pivot creates accessible value rather than just a new narrative.

The economic map at the end of 2025 looks like this:

One more number helps frame the company. As of the report date SaverOne had roughly 35 employees and contractors, and about 69% were in R&D. Even at the end of 2025 this is still first a development-and-commercialization company, and only then a revenue company.

Events And Triggers

What Actually Opened Up On The Business Side

The positive signal: Europe is no longer just a distribution hope. In 2025 it overtook Israel in revenue, NIS 566 thousand versus NIS 450 thousand, after several Cemex-related moves and a broader reference-account layer. In February 2025 the company also signed an agreement with Teva to install the system across its full fleet of 50 delivery trucks, following an initial deployment in 14 trucks. These are not large numbers, but they do show that the product is meeting real customers.

But this is still not scale. The company is explicit that it remains in early commercialization and has not yet generated significant revenue. The PCS disclosure sharpens the point: the maintenance component exists in accounting terms, but the amount allocated to it has been immaterial across the reported periods.

That chart captures the paradox of 2025. The geographic direction improved, but the base is still very small.

VisionWave Changed The Question

The main trigger: On January 26, 2026, SaverOne signed the VisionWave deal. This is not another distribution agreement. It is a three-stage stock exchange that could ultimately bring VisionWave to roughly 51% ownership of SaverOne in exchange for $7 million of VisionWave stock. SaverOne is meant to serve as the operating arm for RF-focused defense and security initiatives, and to receive a worldwide, non-exclusive, royalty-free license to VisionWave RF technology for defense and homeland-security applications.

The less obvious point: This consideration is not free cash. Under the agreement, at least 50% of the economic value of the VisionWave stock, or proceeds from selling it, must be used for development, commercialization, and operation of the RF platform. So even if the deal progresses exactly as planned, a meaningful part of the value is earmarked for the new platform rather than immediate relief at the common-shareholder level.

Stage 1 is already real: On March 5, 2026, shareholders approved the transaction and Stage 1 closed the same day. VisionWave issued 365,610 restricted shares worth roughly $2.75 million based on a five-day VWAP of $7.5031. In exchange, SaverOne committed to issue 148,584 ADSs, representing 6,418,828,800 ordinary shares, equal to 19.99% of the company under the agreement's fully diluted framework.

The economic implication: SaverOne is no longer being screened only as a transportation-safety story. It is now also a company that may change both its end market and its control structure in the same transaction.

The Near-Term Trigger Is Still Capital, Not Sales

The heavy near-term signal: From January 1, 2026 through the filing date, the company sold 17.5068 billion ordinary shares to Yorkville for $2.485 million, of which $569 thousand was used for partial promissory-note repayment. That number makes the market's current checklist obvious. The market is not asking whether the technology is interesting. It is asking how expensive each extra month of runway has become.

The practical blocker: The company explicitly warns that if the ADS price falls below $1 again for another 30 consecutive trading days before October 2026, it may face immediate Nasdaq delisting without another cure period. After the repeated ADS ratio changes in October 2024, February 2025, June 2025, December 2025, and February 2026, that is no longer a footnote. It is the practical screen through which the whole thesis must be read.

That chart does not tell the entire story, but it does show the direction: dilution has long since moved from theoretical risk to day-to-day funding mechanism.

Efficiency, Profitability And Competition

Europe Improved, But The Economics Still Did Not Catch Up

Revenue fell 39.6% in 2025 to NIS 1.016 million. This is not just a weak headline number. It is also a number that says the company still has not built a commercial base large enough to support a public-company cost structure with tens of millions of shekels in R&D, selling, and reporting expense.

The relatively better news is that the decline was not uniform. Israel fell from NIS 1.194 million to NIS 450 thousand, while Europe rose to NIS 566 thousand. So the 2025 problem is not that the product was rejected everywhere. The problem is that even where geographic penetration improves, the absolute scale is still nowhere near large enough to carry the company.

This is the core picture. Even after some operating-loss improvement, the gap between the revenue base and the cost base remains huge.

What Actually Crushed The Margin

Cost of revenue fell to NIS 713 thousand, but the company also recorded a NIS 377 thousand inventory write-down in 2025. Together that was enough to push SaverOne into a gross loss of NIS 74 thousand. That matters because it says the problem is not only sales pace. It is also the quality of inventory relative to the pace at which that inventory is being monetized.

Ending inventory was NIS 3.813 million, almost 3.8 times annual revenue. At the same time, average trade-credit days, after deducting customer advances, were 165 days. Those are classic signs of a commercialization engine that is still not moving at a healthy pace: inventory is running ahead of revenue, and collections are stretched.

The Cost Cuts Happened Around The Technology, Not Through It

R&D expense fell only 2.6% to NIS 18.898 million. Selling and marketing fell 30% to NIS 3.355 million, and G&A fell 13.1% to NIS 8.405 million. In other words, the company did not become less cash hungry because the product started to fund itself. It became somewhat less cash hungry because it cut surrounding cost layers while the technology core remained heavy.

Put differently, what works right now is the technology platform and the ability to generate partnerships. What still does not work is turning that platform into meaningful revenue.

Competition Is Also About Price, Not Just Technology

The company itself says its products are cost-sensitive and exposed to aggressive customer target costs, especially in automotive channels. It also says that meeting OEM quality requirements will require cooperation with manufacturers, process implementation, and further resources. That helps explain why reference wins such as Cemex or Teva do not automatically translate into strong margins or broad rollout. Competition here is not only about who can detect RF signals. It is about who can enter the customer's value chain without being squeezed on price, quality, and timing.

Cash Flow, Debt And Capital Structure

Cash Flow

Precision matters here. The relevant cash lens is all-in cash flexibility. SaverOne does not yet have a mature enough business to justify a normalized cash-generation bridge. The real question is how much cash remains after actual cash uses.

At the end of 2025 the company had NIS 14.144 million of cash. But that number exists only because financing cash inflow reached NIS 32.069 million during the year. Against that, operating cash burn was NIS 29.207 million, investing outflow was NIS 7 thousand, and FX effects reduced cash by another NIS 2.009 million.

That chart says everything. SaverOne did not get through 2025 because the business began producing cash. It got through 2025 because capital markets and funding agreements kept supplying it.

Yorkville Is A Survival Mechanism, Not A Comfort Layer

At year-end, net promissory notes stood at NIS 4.484 million, entirely current. The SEPA III note bears 8% interest, was issued at a 3% discount, and jumps to 18% in an event of default. This is not cheap capital, and it is not flexible capital either.

During 2025 the company sold 9.159 billion ordinary shares to Yorkville for $8.065 million. After the balance sheet date it sold another 17.5 billion shares for $2.485 million. That is the true economics of the bridge period: each extra stretch of time is being bought with more stock.

There is also a lease layer. Total lease liability stood at NIS 673 thousand, of which NIS 469 thousand was current, and the company pays monthly rent of NIS 49,134 through June 30, 2027. This is not the largest liability in the story, but it is another reminder that the fixed-cost base is not small relative to the revenue line.

VisionWave Value Is Not Clean Cash For Common Shareholders

This is where the story becomes more nuanced. The VisionWave deal can improve financing options, open a new end market, and give SaverOne a strategic currency other than Yorkville. But created value and accessible value are not the same thing.

First, the consideration is VisionWave stock, not cash. Second, monetizing it requires registration, liquidity, and a relevant share price. Third, at least 50% of its economic value must be directed into the RF platform. Fourth, as the deal advances, VisionWave may move toward roughly 51% control. So this is not a simple "capital injection into SaverOne." It is a possible control transfer in exchange for a strategic option and outside stock consideration.

Forward Look

Before looking at 2026, four non-obvious conclusions need to be held together:

• Europe is already larger than Israel in revenue, but on a total base of only NIS 1.0 million.
• The bottom-line improvement in 2025 came mainly from lower opex and a non-operating finance line, not from a commercialization break-out.
• The VisionWave deal can change both end-market positioning and control structure at the same time.
• Even after year-end, the pace of equity-funded runway did not slow. It accelerated.

That leads to a clear reading: the coming year looks less like a breakout year and more like a reset-and-proof year. SaverOne is trying to reset its story from a transport-safety commercialization name into a transport-safety story with a defense RF lane. But for that reset to become real improvement, the company has to pass two tests at once.

What Must Happen In The Next 2-4 Quarters

The first test is commercial. DDPS revenue has to move from reference-account and pilot territory into a level that actually changes the top line, not just the customer list. As long as revenue stays around NIS 1 million per year, European expansion is directionally interesting but economically insufficient.

The second test is strategic. The VisionWave agreement has to move beyond story value into actual operating value: genuine integration that achieves Milestone 1, and then a defense or commercial pilot that pushes the company toward Milestone 2. Without that, the VisionWave transaction remains mostly a financing and rebranding event.

The third test is balance-sheet discipline. SaverOne needs to slow its dependence on Yorkville, or at least show that the dilution is now serving a clearly maturing commercial asset. Otherwise even if the technology improves, common shareholders will own less and less of whatever upside eventually appears.

What Would Improve The Read, And What Would Damage It

What would improve the read is a combination of three things: meaningful growth in the legacy revenue base, measurable progress on VisionWave milestones, and a lower pace of equity issuance as a source of time. What would damage it is the mirror image: more stock sales at high pace, more commercialization delay, and a defense pivot that remains conceptual rather than operational.

Risks

Funding, Dilution, And Listing

This is the main risk. Not because the company has no technology, but because its entire path still rests on continuous access to capital markets. SaverOne states explicitly that if the ADS price falls below $1 again for another 30 consecutive trading days before October 2026, it may face immediate Nasdaq delisting. Once that happens, both financing capacity and trading liquidity get materially worse.

A Control Shift Before Proven Economics

The VisionWave deal can be value-creating, but it can also turn SaverOne into the operating arm of a strategic partner before the company has proven stand-alone commercialization at meaningful scale. If all three stages are completed, VisionWave would reach roughly 51% ownership. That is not automatically negative. But it does mean shareholders have to ask not only whether value is being created, but who controls it, when it becomes accessible, and through which layer.

Controls And Disclosure Quality

As of year-end 2025, management concluded that internal control over financial reporting was not effective because of insufficient accounting personnel and lack of segregation of duties. That is already a yellow flag on its own.

There are also disclosure frictions that are hard to ignore. The cover page states that ordinary shares outstanding at December 31, 2025 were 29.96 billion, while the audited equity note shows 10.26 billion. The ordered-and-installed-system KPI is also anchored to March 19, 2025 even though the annual document was filed only in late March 2026. None of that proves a deeper problem by itself, but it does reduce confidence in a clean per-share reading.

Commercialization Is Still Open

The company itself says the revenue decline in Israel reflected longer decision processes among current and prospective customers. It also says it still has not generated significant recurring revenue. So even after the reference-account progress, the core risk has not changed: the technology may be real, but the pace of adoption is still not strong enough to carry the cost base, the public-company burden, and the dilution required to keep funding the bridge.

Conclusions

SaverOne ends 2025 in a very different place from where it started the year. It is no longer only a distracted-driving technology story. It is also an option on an RF defense platform. That is what keeps the story interesting right now. What weighs on it is that the existing economics are still too small, and the runway is still being funded mainly through the capital markets and repeated share issuance.

Over the short to medium term, the market will not really ask whether the patents are interesting. It will ask whether VisionWave is advancing through milestones, whether DDPS revenue is moving to a meaningful level, and whether the pace of dilution eases before Nasdaq listing risk reopens.

Current thesis: SaverOne is currently more a funded strategic option than a proven commercial business.

What changed: The story moved from a small transportation commercialization name toward a company leaning on both a defense pivot and a possible change of control.

Counter-thesis: If VisionWave delivers integration and a pilot on time, and if the current reference accounts mature into larger orders, part of the recent dilution may later look like the cost of crossing into a much larger market.

What could change the market's reading in the short to medium term: Milestone 1 and Milestone 2 under the VisionWave agreement, actual revenue rather than customer names, and one very practical question, can the company get through 2026 without another aggressive dilution cycle.

Why this matters: Because with SaverOne the key question is no longer only whether the company has interesting technology, but whether any accessible shareholder value remains after the funding structure, the issuances, and the possibility of control change.

For the thesis to improve over the next 2-4 quarters, SaverOne needs real revenue growth, operational progress with VisionWave, and lower dependence on stock issuance as a source of time. What would weaken it is the opposite: more aggressive share issuance, more commercialization delay, and a defense pivot that stays at agreement level without visible operating impact.